A Real-World Longitudinal Study in Non-Functioning Pituitary Incidentalomas: A PRECES Micro-Adenomas Sub-Analysis

Overview

Journal Diseases

Date 2024 Oct 25

PMID 39452483

Authors

Mihai Costachescu

Claudiu Nistor

Ana Valea

Oana-Claudia Sima

Adrian Ciuche

Mihaela Stanciu

Mara Carsote

Mihai-Lucian Ciobica

Affiliations

Soon will be listed here.

Abstract

Incidentalomas have an increasing incidence all over the world due to a larger access to imaging assessments, and endocrine incidentalomas make no exception in this matter, including pituitary incidentalomas (PIs). Our objective was to analyse the dynamic changes amid a second computed tomography (CT) scan after adult patients were initially confirmed with a PI (non-functioning micro-adenoma). This was a multi-centric, longitudinal, retrospective study in adults (aged between 20 and 70 y) amid real-world data collection. We excluded patients who experienced baseline pituitary hormonal excess or deficiency or those with tumours larger than 1 cm. A total of 117 adults were included (94.02% females) with a mean age of 43.86 ± 11.99 years, followed between 6 and 156 months with a median (M) of 40 months (Q1 Q3: 13.50, 72.00). At the time of PI diagnosis, the transverse diameter had a mean value of 0.53 ± 0.16 cm, the longitudinal mean diameter was 0.41 ± 0.13 cm, and the largest diameter was 0.55 ± 0.16 cm. No PI became functioning during follow-up, neither associated hypopituitarism nor increased >1 cm diameter. A total of 46/117 (39.32%) patients had a larger diameter during follow-up (increase group = IG) versus a non-increase group (non-IG; N = 71, 60.68%) that included the subjects with stationary or decreased diameters. IG had lower initial transverse, longitudinal, and largest diameter versus non-IG: 0.45 ± 0.12 versus 0.57 ± 0.17 ( < 0.0001), 0.36 ± 0.11 versus 0.43 ± 0.13 ( = 0.004), respectively, 0.46 ± 0.12 versus 0.6 ± 0.16 ( < 0.0001). IG versus non-IG had a larger period of surveillance: M (Q1, Q3) of 48 (24, 84) versus 32.5 (12, 72) months ( = 0.045) and showed similar age, pituitary hormone profile, and tumour lateralisation at baseline and displayed a median diameter change of +0.14 cm versus -0.03 cm ( < 0.0001). , a rather high percent of patients might experience PI diameter increase during a longer period of follow-up, including those with a smaller initial size, while the age at diagnosis does not predict the tumour growth. This might help practitioners with further long-term surveillance protocols.

References

Gontarz-Nowak K, Szklarz M, Szychlinska M, Matuszewski W, Bandurska-Stankiewicz E . A Brief Look at Hashimoto's Disease, Adrenal Incidentalomas, Obesity and Insulin Resistance-Could Endocrine Disruptors Be the Other Side of the Same Coin?. Medicina (Kaunas). 2023; 59(7). PMC: 10385892. DOI: 10.3390/medicina59071234. View

Wang M, Meyer J, Danesh-Meyer H . Neuro-ophthalmic evaluation and management of pituitary disease. Eye (Lond). 2024; 38(12):2279-2288. PMC: 11306754. DOI: 10.1038/s41433-024-03187-x. View

Morinaga Y, Abe I, Nii K, Hanada H, Takemura Y, Takashi Y . Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgery. Medicine (Baltimore). 2020; 99(44):e22713. PMC: 7598882. DOI: 10.1097/MD.0000000000022713. View

Baldo F, Marin M, Murru F, Barbi E, Tornese G . Dealing With Brain MRI Findings in Pediatric Patients With Endocrinological Conditions: Less Is More?. Front Endocrinol (Lausanne). 2022; 12:780763. PMC: 8791386. DOI: 10.3389/fendo.2021.780763. View

Donovan L, Corenblum B . The natural history of the pituitary incidentaloma. Arch Intern Med. 1995; 155(2):181-3. View

Kageyama K, Nishiyama M . Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy. Cancers (Basel). 2023; 15(23). PMC: 10705121. DOI: 10.3390/cancers15235526. View

Sanno N, Oyama K, Tahara S, Teramoto A . [Clinical aspects of pituitary incidentalomas]. Nihon Rinsho. 2004; 62(5):946-50. View

Oyama K, Sanno N, Tahara S, Teramoto A . Management of pituitary incidentalomas: according to a survey of pituitary incidentalomas in Japan. Semin Ultrasound CT MR. 2005; 26(1):47-50. DOI: 10.1053/j.sult.2004.10.001. View

Giraldi E, Allen J, Ioachimescu A . Pituitary Incidentalomas: Best Practices and Looking Ahead. Endocr Pract. 2022; 29(1):60-68. DOI: 10.1016/j.eprac.2022.10.004. View

10.

Costanzo R, Scalia G, Strigari L, Ippolito M, Paolini F, Brunasso L . Nuclear medicine imaging modalities to detect incidentalomas and their impact on patient management: a systematic review. J Cancer Res Clin Oncol. 2024; 150(7):368. PMC: 11272692. DOI: 10.1007/s00432-024-05891-3. View

11.

Tsukamoto T, Miki Y . Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 2. Neoplasms other than PitNET and tumor-mimicking lesions. Jpn J Radiol. 2023; 41(8):808-829. PMC: 10366287. DOI: 10.1007/s11604-023-01407-0. View

12.

Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y . A survey of pituitary incidentaloma in Japan. Eur J Endocrinol. 2003; 149(2):123-7. DOI: 10.1530/eje.0.1490123. View

13.

Kolbeinsson H, Dandamudi S, Gira J, Krech L, Pounders S, Fisk C . Expecting the unexpected: incidental findings at a level 1 trauma center. Emerg Radiol. 2023; 30(3):343-349. DOI: 10.1007/s10140-023-02138-5. View

14.

Nistor C, Ciuche A, Cucu A, Serban B, Cursaru A, Cretu B . Clavicular Malignancies: A Borderline Surgical Management. Medicina (Kaunas). 2022; 58(7). PMC: 9315479. DOI: 10.3390/medicina58070910. View

15.

Hamblin R, Fountas A, Levy M, Karavitaki N . UK practice on incidentally detected non-functioning pituitary microadenomas: analysis of two national surveys during a 12-year interval. Pituitary. 2022; 26(1):94-104. PMC: 9908737. DOI: 10.1007/s11102-022-01290-4. View

16.

Nistor C, Ciuche A, Constantinescu I . EMERGENCY SURGICAL TRACHEAL DECOMPRESSION IN A HUGE RETROSTERNAL GOITER. Acta Endocrinol (Buchar). 2019; 13(3):370-374. PMC: 6516576. DOI: 10.4183/aeb.2017.370. View

17.

Tahara S, Hattori Y, Suzuki K, Ishisaka E, Teramoto S, Morita A . An Overview of Pituitary Incidentalomas: Diagnosis, Clinical Features, and Management. Cancers (Basel). 2022; 14(17). PMC: 9454484. DOI: 10.3390/cancers14174324. View

18.

Westall S, Aung E, Kejem H, Daousi C, Thondam S . Management of pituitary incidentalomas. Clin Med (Lond). 2023; 23(2):129-134. PMC: 11046515. DOI: 10.7861/clinmed.2023-0020. View

19.

Unger N, Theodoropoulou M, Schilbach K . [Clinically active pituitary tumors]. Inn Med (Heidelb). 2024; 65(7):672-680. DOI: 10.1007/s00108-024-01729-9. View

20.

Souteiro P, Maia R, Santos-Silva R, Figueiredo R, Costa C, Belo S . Pituitary incidentalomas in paediatric age are different from those described in adulthood. Pituitary. 2019; 22(2):124-128. DOI: 10.1007/s11102-019-00940-4. View